Prevention of recurrent idiopathic venous thromboembolism

Circulation

Volumn 110, Issue 24 SUPPL., 2004, Pages

  Goldhaber, Samuel Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Deep vein thrombosis; Idiopathic venous thromboembolism; Pulmonary embolism; Warfarin; Ximelagatran

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; COUMARIN DERIVATIVE; D DIMER; PLACEBO; PROTHROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; CHRONIC DISEASE; CLINICAL TRIAL; COST; DEEP VEIN THROMBOSIS; DRUG EFFICACY; GENE MUTATION; HEALTH CARE PERSONNEL; HUMAN; IDIOPATHIC DISEASE; LONG TERM CARE; NOMOGRAM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; REVIEW; RISK FACTOR; THROMBOSIS PREVENTION; ULTRASOUND; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CHRONIC DISEASE; HUMANS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; REGISTRIES; VENOUS THROMBOSIS;

EID: 10944263703     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000150641.65000.f2     Document Type: Review

References (17)

1. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
2. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761-768.
3. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769-774.
4. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of 6 weeks with 6 months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661-1665.
5. Agnelli G, Prandoni P, Santamaria MG, et al. for the Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med. 2001;345:165-169.
6. Agnelli G, Prandoni P, Becattini C, et al. for the Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139:19-25.
7. Schulman S, Granqvist S, Holmstrom M, et al. for the Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336:393-398.
8. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
9. Ridker PM, Goldhaber SZ, Danielson E, et al. for the PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-1434.
10. Kearon C, Ginsberg JS, Kovacs MJ, et al. for the Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-639.
11. Schulman S, Wahlander K, Lundstrom T, et al. for the THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349:1713-1721.
12. Palareti G, Legnani C, Cosmi B, et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002;87:7-12.
13. Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003;108:313-318.
14. Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-960. Summary for patients in: Ann Intern Med. 2002;137:955-960.
15. Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-960. Summary for patients in: Ann Intern Med. 2002;137:955-960.
16. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523-526.
17. Vink R, Kraaijenhagen RA, Levi M, Buller HR. Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model. J Thromb Haemost. 2003;1:2523-2530.